Recombinant tissue plasminogen activator (rTPA) management for first onset acute ischemic stroke with covid -19 and non-covid -19 patients

OBJECTIVES: Cerebrovascular stroke (CVS) is one of the well-known complications of coronavirus-2019 (Covid-19), but less is known about the outcome and safety of thrombolytic therapy in these patients. In this study we compare the efficacy and safety of Tissue plasminogen activator (rTPA) in acute i...

Descripción completa

Detalles Bibliográficos
Autores principales: Khedr, Eman M, Abdelwarith, Ahmed, Moussa, Gehad, Saber, Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868389/
https://www.ncbi.nlm.nih.gov/pubmed/36701854
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2023.107031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868389/
https://www.ncbi.nlm.nih.gov/pubmed/36701854
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2023.107031

Ejemplares similares